Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e321-e323. doi: 10.1016/j.clml.2019.03.020. Epub 2019 Mar 29.

¹ Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.
² Hematology, Città della Salute e della Scienza Hospital and University, Torino, Italy.
³ Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy.
⁴ Hematology Unit, S. Maria delle Croci Hospital, Ravenna, Italy.
⁵ Hematology unit, Azienda ospedaliera universitaria Sant'Andrea, Roma, Italy.
⁶ Department of Medical Sciences, Section of Hematology, University of Modena and Reggio Emilia, Modena, Italy.
⁷ Hematology and Bone Marrow Transplant Unit, Verona University, Verona, Italy.
⁸ Division of Hematology IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
⁹ Hematology Unit, SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
¹⁰ Division of Hematology, AOU Policlinico-OVE, Department of Surgery and Medical Specialties, University of Catania, Catania, Italy.
¹¹ Division of Hematology, ASST Niguarda Hospital, Milano, Italy.
¹² Hematology, AOU Careggi, Firenze, Italy; Hematology Azienda San Camillo Forlanini, Roma, Italy.
¹³ Azienda Ospedaliera S. Croce e Carle - Hematology Department and BMT Unit, Cuneo, Italy.
¹⁴ Unit of Hematology with Transplantation Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.
¹⁵ Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy. Electronic address: pierluigi.zinzani@unibo.it.

No abstract available

Keywords: Diffuse large B-cell lymphoma; Immunomodulatory drug; Refractory; Relapsed; Salvage therapy.

MeSH terms